Join us on this podcast episode featuring Prof. Maria Teresa Voso (Tor Vergata University of Rome, Italy) as she offers her insights on the latest advancements in precision medicine for diagnosing and treating myelodysplastic syndromes (MDS).
In this interview with our EHA host, Dr. Isabel Olivera Martinez, Prof. Voso begins by explaining how the use of NGS myeloid panels in identifying individual myeloid mutations enhances the diagnostic accuracy of MDS. Our guest then discusses the novelties in the 2022 WHO and ICC MDS classifications and the significance of germline predisposition. Furthermore, she explores the emerging targeted therapies for MDS, including lenalidomide, luspatercept, and imetelstat.
This episode offers a comprehensive overview of the evolving landscape of MDS diagnosis and management, highlighting the importance of personalized approaches in improving patient outcomes.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Maria Teresa Voso
This is the ninth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Interested in more content related to MDS? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe